OncoMatch/Clinical Trials/NCT05587543
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Is NCT05587543 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including CAR and TCR for nasopharyngeal carcinoma.
Treatment: CAR · TCR — This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV positive by in situ hybridization (Eber-FISH)
Ebv-positive nasopharyngeal carcinoma was diagnosed by in situ hybridization with Ebers (Eber-fish)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy — recurrent/metastatic
Recurrent/metastatic nasopharyngeal carcinoma patients who had previously failed second-line or more systemic therapy
Cannot have received: Chimeric antigen receptor T-cell therapy
Treated with Chimeric antigen receptor t-cell therapy within six months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05587543 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Chimeric antigen receptor T-cell therapy disqualifies patients from enrollment.
Does this trial require EBV?
Yes, EBV positive by in situ hybridization (Eber-FISH) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages